If you’re at all interested in what the next decade has in store for investors in the Genomics and Biotech Sector, stay tuned. The innovation, disruption, and breakthroughs taking place at companies in this space are destined to be among the most exciting for investors in the period ahead.
It was an honour to chat with Emerge Canada CEO, Lisa Langley and ARK Investments’ Ali Urman about the Genomics and Biotech Sector, as defined by the holdings of the Emerge ARK Genomics and Biotech ETF (ticker: EAGB:NEO).
Lisa Langley is CEO at Emerge Canada Inc. Her firm is the sponsor of Emerge ARK ETFs. Lisa Langley’s firm, Emerge Canada launched the Emerge Canada Inc. in 2019 to bring Canadians actively managed, innovation focused investment strategies. Emerge offers ETFs, Mutual Funds and Separate Accounts, sub-advised by ARK Investments, led by investing legend and household name, Cathie Wood.
Ali Urman is ARK Invest’s Genomic Revolution analyst, responsible for the company’s research on Gene editing, DNA sequencing, Stem cell technologies & Immunotherapy.
We discuss the Genomic revolution – Ali explains the transformative convergence of Next-generation DNA sequencing, Artificial Intelligence & CRISPR gene editing. We talked about some of the revolutionary medical breakhthroughs borne out of the massive progress taking place in biotechnology. Following this we get into how ARK picks their Genomics stocks, and the once in decades opportunity markets have handed investors post the recent market drawdowns of the last year, to accumulate diversified holdings in the space. Enjoy the episode.
====================
Emerge ARK Genomics & Biotech ETF -ticker: EAGB
====================
ARK Investments – Big Ideas 2022
Ali Urman’s section at pg. 77
ARK Investments Big Ideas 2022
====================
Copyright © AdvisorAnalyst.com